CD274 and glioblastoma: Interestingly, the prolonged survivors had lower intratumoral PD-L1 expression thus favoring the eventual combination with immune checkpoint inhibitors.75 In this regard, a phase I/II trial (NCT03750071) is evaluating VXM01 in combination with Avelumab in recurrent GBM.